{"nct_id":"NCT03970837","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"TERMINATED","status_verified_date":"2023-11","start_date":"2019-06-05","start_date_type":"ACTUAL","primary_completion_date":"2021-10-29","primary_completion_date_type":"ACTUAL","completion_date":"2023-01-18","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["GSK"]}